Mono Pharmacare (NSE:MONOPHARMA) EBIT: ₹50 Mil (TTM As of Sep. 2025)


NSE:MONOPHARMA Mono Pharmacare Ltd NSE:MONOPHARMA
9 GF Score
Price ₹11.00
! 6 Warning Signs
View Full Analysis

What is Mono Pharmacare EBIT?

Mono Pharmacare NSE:MONOPHARMA -1.79% 9 EBIT is ₹50 Mil as of Sep. 2025. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 9/100. The stock has 6 warning signs investors should review.

Mono Pharmacare's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2025 was ₹17 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2025 was ₹50 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Mono Pharmacare's annualized ROC % for the quarter that ended in Sep. 2025 was 0.69%. Mono Pharmacare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was 4.19%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Mono Pharmacare's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was 6.87%.

Mono Pharmacare  (NSE:MONOPHARMA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Mono Pharmacare's annualized ROC % for the quarter that ended in Sep. 2025 is calculated as:

ROC % (Q: Sep. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Sep. 2025 ))/ count )
=34.262 * ( 1 - 81.96% )/( (887.105 + 896.196)/ 2 )
=6.1808648/891.6505
=0.69 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1100.55 - 206.468 - ( 6.977 - max(0, 527.755 - 1089.873+6.977))
=887.105

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1193.37 - 284.779 - ( 12.395 - max(0, 615.368 - 1183.159+12.395))
=896.196

Note: The Operating Income data used here is two times the semi-annual (Sep. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Mono Pharmacare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Sep. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=34.542/( ( (10.001 + max(831.129, 0)) + (9.455 + max(799.583, 0)) )/ 2 )
=34.542/( ( 841.13 + 809.038 )/ 2 )
=34.542/825.084
=4.19 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(418.875 + 553.861 + 110.16) - (206.468 + 0 + 45.299)
=831.129

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(609.853 + 516.076 + 3.4490000000001) - (284.779 + 0 + 45.016)
=799.583

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Mono Pharmacare's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2025 )
=50.281/732.281
=6.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mono Pharmacare EBIT Related Terms

Mono Pharmacare EBIT Historical Data

* Premium members only.

The historical data trend for Mono Pharmacare's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mono Pharmacare EBIT Chart

Mono Pharmacare Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
EBIT
8.14 12.06 29.99 60.73 80.16

Mono Pharmacare Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
EBIT Get a 7-Day Free Trial Premium Member Only 38.55 22.17 47.15 33.01 17.27

Mono Pharmacare EBIT Competitor Comparison

For the Pharmaceutical Retailers subindustry, Mono Pharmacare's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mono Pharmacare EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Mono Pharmacare's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mono Pharmacare's EV-to-EBIT falls into.


NSE:MONOPHARMA
9GF Score
Mono Pharmacare Ltd NSE:MONOPHARMA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mono Pharmacare EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹50 Mil mean?
Mono Pharmacare (NSE:MONOPHARMA) has a EBIT of ₹50 Mil as of Sep. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Mono Pharmacare.
Is Mono Pharmacare's EBIT too high?
Mono Pharmacare's current EBIT is ₹50 Mil. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's EBIT compare to competitors?
Mono Pharmacare's EBIT of ₹50 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Mono Pharmacare. Mono Pharmacare's current EBIT is ₹50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current EBIT of ₹50 Mil. The current EBIT is ₹50 Mil. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current EBIT is ₹50 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mono Pharmacare Business Description

Address 1A, Krinkal Apartment, Opposite Mahalaxmi Temple, Paldi, Ahmedabad, GJ, IND, 380007
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score

Get the complete analysis for NSE:MONOPHARMA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹11.00
Price